Qiagen N.V.
Financials
Valuation Metrics
Qiagen N.V.'s Market Cap is $10.36B. At end of 2025 it was $9.84B. Ranked #893 of 3,116 in US market (top 29%), #615 of 1,644 on NYSE (top 37%), #67 of 203 in Health Care Equipment & Services (top 33%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $10.36B | US#893/3,116 Sec#67/203 |
| Revenue | $2.10B | US#1,388/3,116 Sec#89/203 |
| Net Income | $409M | US#931/3,116 Sec#50/203 |
| Total Assets | $5.89B | US#1,322/3,116 Sec#62/203 |
| Net Assets | $3.36B | US#902/3,116 Sec#46/203 |
| Employees | 5,500 | US#1,177/3,116 Sec#86/203 |
| Value | ||
| P/E | 25.30x | US#1,393/3,116 Sec#45/203 |
| P/B | 3.08x | US#1,797/3,116 Sec#92/203 |
| PEG | 2.63x | US#1,082/3,116 Sec#54/203 |
| P/S | 4.93x | US#2,281/3,116 Sec#149/203 |
| EV/EBITDA | 15.26x | US#1,526/3,116 Sec#58/203 |
| FCF Yield | 4.32% | US#1,528/3,116 Sec#76/203 |
| Profitability | ||
| ROE | 12.19% | US#1,136/3,116 Sec#54/203 |
| ROA | 6.95% | US#800/3,116 Sec#50/203 |
| Op. Margin | 25.33% | US#659/3,116 Sec#16/203 |
| Revenue Growth | 2.96% | US#1,956/3,116 Sec#151/203 |
| Earnings Growth | 9.62% | US#1,075/3,116 Sec#57/203 |
| Financial Health | ||
| Debt Ratio | 75.39% | US#831/3,116 Sec#86/203 |
| Total Debt | $1.64B | US#1,269/3,116 Sec#64/203 |
| FCF | $448M | US#947/3,116 Sec#54/203 |
| Cash | $769M | US#816/3,116 Sec#43/203 |
| Current Ratio | 2.85x | US#831/3,116 Sec#82/203 |
| Net Debt/EBITDA | 1.19x | US#1,044/3,116 Sec#60/203 |
| Dividend | ||
| Div. Yield | 0.52% | US#1,511/3,116 Sec#40/203 |
| Performance | ||
| 1Y Return | 8.37% | US#1,609/3,116 Sec#118/203 |
| 1M Return | 14.74% | US#480/3,116 Sec#43/203 |
| From 52W High | -13.16% | US#1,072/3,116 Sec#96/203 |
| 1Y MDD | -41.38% | US#1,994/3,116 Sec#127/203 |
| Trading | ||
| Volume | 3,963,072 shares | US#581/3,116 Sec#30/203 |
| Trading Value | $199M | US#629/3,116 Sec#51/203 |
| Per Share | ||
| EPS | $1.98 | US#1,340/3,116 Sec#68/203 |
| BPS | $16.28 | US#1,450/3,116 Sec#80/203 |
Company Info
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.